Search
Results: 4
Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease
Sonali Wijetilleka, Chetan Mukhtyar, David Jayne, Aftab Ala, Philip Bright, Hector Chinoy, Lorraine Harper, Majid Kazmi, Sorena Kiani-Alikhan, Charles Li, Siraj Misbah, Louise Oni, Fiona Price-Kuehne, Alan Salama, Sarita Workman, David Wrench, Mohammed Yousuf Karim
Feb 24, 2020
BACKGROUND: Consensus guidelines are not available for the use of immunoglobulin replacement therapy (IGRT) in patients developing iatrogenic secondary antibody deficiency following B-cell targeted therapy (BCTT) in autoimmune...
Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.
Sonali Wijetilleka, David R Jayne, Chetan Mukhtyar, Aftab Ala, Philip D Bright, Hector Chinoy, Lorraine Harper, Majid A Kazmi, Sorena Kiani-Alikhan, Charles K Li, Siraj A Misbah, Louise Oni, Fiona E Price-Kuehne, Alan D Salama, Sarita Workman, David Wrench, Mohammed Yousuf Karim
Nov 27, 2019
OBJECTIVES: The association of B cell targeted therapies with development of hypogammaglobulinaemia and infection is increasingly recognized. Our aim was to develop consensus recommendations for immunoglobulin replacement...
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Joanna Tieu, Rona M Smith, Seerapani Gopaluni, Dinakantha S Kumararatne, Mark McClure, Ania Manson, Sally Houghton, David RW Jayne
Jun 07, 2021
OBJECTIVE: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement...
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
Helena Marco, Rona M Smith, Rachel B Jones, Mary-Jane Guerry, Fausta Catapano, Stella Burns, Afzal N Chaudhry, Kenneth GC Smith, David RW Jayne
Sep 05, 2018
BACKGROUND: Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab...